AIMT
AIMT Articles
The prize for Nestle in its acquisition of Aimmune Therapeutics is Palforzia, the world’s first treatment for a food allergy.
Published:
Consumer products giant Nestlé has agreed to acquire Aimmune Therapeutics, maker of a peanut-allergy treatment. The deal is valued at $2.6 billion, including Nestlé's existing stake Aimmune.
Published:
Monday's top analyst calls included AbbVie, AES, AT&T, Boeing, Carnival, CME, Coca-Cola, Comcast, Honeywell, Lululemon Athletica, Netflix, Shopify, Starbucks and Twitter.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.